Alterity Therapeutics to Present New Data on ATH434 at the
MELBOURNE, Australia and SAN FRANCISCO, April 10, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”),...
Source: globenewswire.com
📰 Moderate Affinity News
Moderate Affinity News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Moderate Affinity. Real-time updates on events, politics, business and more.
Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024
MELBOURNE, Australia and SAN FRANCISCO, April 10, 2024 -- Alterity Therapeutics , a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today...
Source: marketscreener.com
Alterity Therapeutics to Present New Data at the Upcoming
– Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s Disease to be Presented at International Conference – – Baseline Biomarker Data to...
Source: globenewswire.com
Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting
– Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s Disease to be Presented at International Conference – – Baseline Biomarker Data to be Presented from Ongoing ATH434-201...
Source: marketscreener.com
Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 ...
– Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s Disease to be Presented at International Conference –
Source: eagletribune.com
Alterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson's Disease -December 04, 2023 at 07:26 am EST
- ATH434 improved motor performance and general function – - Webcast to be held this week to discuss new data and recent clinical progress – MELBOURNE, Australia and SAN FRANCISCO, Dec. 04,...
Source: marketscreener.com